Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22394150 | 0.97 | PKLR (0.82) | PKLRPKM | |
| SCHEMBL2702549 | 0.94 | PKM (0.75) | PKLRPKM | |
| SCHEMBL2702840 | 0.94 | PKLR (0.79) | PKLRPKM | |
| SCHEMBL2704287 | 0.93 | PKLR (0.76) | PKLRPKM | |
| SCHEMBL2703471 | 0.92 | PKM (0.78) | PKLRPKM | |
| SCHEMBL2702629 | 0.92 | PKLR (0.81) | PKLRPKM | |
| SCHEMBL22394091 | 0.92 | PKLR (0.78) | PKLRPKM | |
| SCHEMBL2704770 | 0.92 | PKLR (0.75) | PKLRPKM | |
| SCHEMBL12964598 | 0.92 | PKLR (0.78) | PKLRPKM | |
| SCHEMBL2704705 | 0.92 | PKLR (0.73) | PKLRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428376-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240360083-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11866411-B2 | Therapeutic compounds and compositions | Agios Pharmaceutical, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3406251-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988448-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-2448582-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2448582-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002817-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002817-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988448-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
| US-12428376-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
| US-20240360083-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
| US-11866411-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | PKLR 23/4885PKM 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.